News

RTX Earnings Top Wall Street Estimates, but the Stock Is Down. Blame Tariffs.
The stock is down, but the reaction is nothing like what happened in April. That’s a positive for investors.
What's Happening With PepsiCo Stock?
PepsiCo’s stock jumped 7% on July 17 after a robust Q2 earnings announcement. The company not only surpassed expectations but ...
Verizon’s stock is having its best day in over a year. Here’s the big highlight from earnings.
Shares of Verizon VZ are up 4% in premarket trading Monday, after the company said it expects $19.5 billion to $20.5 billion ...
Halliburton Stock Slips. CEO Sees Oil Services Demand Weakening.
Halliburton, the oil services provider, reported earnings that were in line with Wall Street expectations on Tuesday but a ...
ATI: Tailwinds And Momentum Could Carry This Defense Stock Higher
ATI Inc. thrives on defense sector strength, robust fundamentals, and global demand. Click here to see why ATI stock is a Buy ...
'It isn't different this time': Why one strategist sees excessive investor euphoria driving a 15% stock plunge
Markets have already priced in the best-case scenario. Investors are in store for a pullback, Evercore's Julian Emanuel said.
Opendoor Stock Soared More Than 40% Monday—Watch These Price Levels
Opendoor shares surged Monday as retail traders bid up Wall Street’s newest meme stock sensation. Monitor these vital chart ...
Wells Fargo's Mike Mayo on state of the banking sector, future of regulation and top bank stock
Mike Mayo, Wells Fargo Securities senior bank analyst, joins 'Squawk Box' to discuss the state of the banking sector, what to ...
Korea Presidential Aide Pushes for Gradual Corporate Stock Plan
The South Korean president’s push to cancel listed companies’ treasury stock purchases will strengthen corporate governance ...
What Analysts Think of Intel Stock Ahead of Earnings
Intel is scheduled to report second-quarter results after the closing bell Thursday, with analysts tracked by Visible Alpha ...
Sarepta Stock Falls. Why It’s Caving In to the FDA and What Comes Next.
The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.